Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

The impact of reference-pricing systems in Europe: a literature review and case studies.

Dylst P, Vulto A, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):729-37. doi: 10.1586/erp.11.70. Review.

PMID:
22098289
2.

The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.

Fraeyman J, Van Hal G, Godman B, Beutels P.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):141-51. doi: 10.1586/erp.12.88.

PMID:
23402454
3.

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.

Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A.

Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):121-9. doi: 10.1586/erp.10.87.

PMID:
21351864
4.

European healthcare policies for controlling drug expenditure.

Ess SM, Schneeweiss S, Szucs TD.

Pharmacoeconomics. 2003;21(2):89-103.

PMID:
12515571
5.

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.

Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P.

Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):475-84. doi: 10.1586/erp.09.43.

PMID:
19817531
6.

Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.

Abuelkhair M, Abdu S, Godman B, Fahmy S, Malmström RE, Gustafsson LL.

Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):115-24. doi: 10.1586/erp.11.90.

PMID:
22280201
7.

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications.

Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M, Laius O, McGinn D, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, Tulunay FC, Vlahović-Palčevski V, Wendykowska K, Wettermark B, Zara C, Gustafsson LL.

Expert Rev Pharmacoecon Outcomes Res. 2010 Dec;10(6):707-22. doi: 10.1586/erp.10.72.

PMID:
21155704
8.

Impact of European pharmaceutical price regulation on generic price competition: a review.

Puig-Junoy J.

Pharmacoeconomics. 2010;28(8):649-63. doi: 10.2165/11535360-000000000-00000. Review.

PMID:
20515079
9.

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.

Woerkom Mv, Piepenbrink H, Godman B, Metz Jd, Campbell S, Bennie M, Eimers M, Gustafsson LL.

J Comp Eff Res. 2012 Nov;1(6):527-38. doi: 10.2217/cer.12.52.

PMID:
24236472
10.

Demand-side policies to encourage the use of generic medicines: an overview.

Dylst P, Vulto A, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):59-72. doi: 10.1586/erp.12.83. Review.

PMID:
23402447
11.

Pattern of statins' utilization at Ramathobodi Hospital, 2005 to 2007.

Pattanaprateep O, Pongcharoensuk P, Suvanakoot P, Kaojarern S.

J Med Assoc Thai. 2010 Oct;93(10):1223-31.

PMID:
20973328
12.

Analysis of French generic medicines retail market: why the use of generic medicines is limited.

Dylst P, Vulto A, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):795-803. doi: 10.1586/14737167.2014.946011. Epub 2014 Aug 6. Review.

PMID:
25095903
13.

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs.

Godman B, Schwabe U, Selke G, Wettermark B.

Pharmacoeconomics. 2009;27(5):435-8. doi: 10.2165/00019053-200927050-00010. No abstract available.

PMID:
19586083
14.

Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.

Fraeyman J, Verbelen M, Hens N, Van Hal G, De Loof H, Beutels P.

Appl Health Econ Health Policy. 2013 Oct;11(5):543-52. doi: 10.1007/s40258-013-0054-9.

PMID:
24062144
15.

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, Sturm H.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005979. Review. Update in: Cochrane Database Syst Rev. 2014;10:CD005979.

PMID:
16625648
16.

Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.

Bennie M, Godman B, Bishop I, Campbell S.

Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):125-30. doi: 10.1586/erp.11.98.

PMID:
22280202
17.

Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.

Ioannides-Demos LL, Ibrahim JE, McNeil JJ.

Pharmacoeconomics. 2002;20(9):577-91. Review.

PMID:
12141886
18.

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.

Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M.

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):469-82. doi: 10.1586/14737167.2013.820956. Review.

PMID:
23977975
19.

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions.

Markovic-Pekovic V, Skrbić R, Godman B, Gustafsson LL.

Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):661-71. doi: 10.1586/erp.12.48.

PMID:
23186404
20.

Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.

Kaló Z, Muszbek N, Bodrogi J, Bidló J.

Health Policy. 2007 Mar;80(3):402-12. Epub 2006 May 30.

PMID:
16730848

Supplemental Content

Support Center